Wyeth says the FDA has given fast-track status for its drug, temsirolimus, designed to treat patients with advanced kidney cancer. The drug, currently in a phase III trial studying its survival benefit, prevents the enzyme, rapamycin kinase, from signaling a cancer cell to divide.

Full Story:

Related Summaries